ESMO Asia | Novel immune checkpoint inhibitor combinations for TNBC treatment

Michail Ignatiadis, MD, PhD, Institut Jules Bordet, Brussels, Belgium, discusses novel combinations of immune checkpoint inhibitors in triple-negative breast cancer (TNBC) treatment. The KEYNOTE-522 (NCT03036488) regimen combines pembrolizumab with weekly paclitaxel and carboplatin, followed by anthracycline-based therapy. Studies are combining all effective immunotherapies and working to address to what extent they can replace doxorubicin and cyclophosphamide (AC), and if antibody-drug conjugates can be used rather than traditional chemotherapy. This interview took place at the European Society for Medical Oncology (ESMO) Asia 2023 Congress in Singapore.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.